MedTrace Logo

Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

NCT07160686 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1456

Last updated 2025-09-08

No results posted yet for this study

Summary

The aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments. Apixaban is a type of oral anticoagulant ("blood thinner") that makes the blood less sticky to prevent blood clots forming.

The trial is trying to find out if apixaban it can reduce blood clots in people with lung cancer.

Participants will receive the following treatment:

• Apixaban or placebo, 2.5mg taken by mouth twice a day for 6 months. This treatment will be taken in addition to any treatment that they are receiving to treat their lung cancer.

Participants will need to:

* Sign a consent form to enter the trial.
* Take the trial treatment as directed by the research team
* Complete a participant diary to record when they took the trial treatment
* Complete the Quality of Life and Health resource use questionnaires.
* Female participants of childbearing potential must use adequate contraception during the trial and for at least 2 days after trial treatment has finished.

Conditions

  • Thromboprophylaxis

Interventions

DRUG

Apixaban

apixaban 2.5mg twice a day for 6 months

OTHER

Placebo

Placebo twice a day for 6 months

Sponsors & Collaborators

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Michael Newnham, MBChB, MSc, MRCP, PhD · University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2029-09-30
Completion
2030-03-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07160686 on ClinicalTrials.gov